Finance

Lists
TNXP:NASDAQ
Tonix Pharmaceuticals Holding Corp
7,30 USD
+0,27%
(+0,020) 1D
7,35 USD
+0,68% (+0,050)
Pre-market
Closed: 9-окт., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNXP...
Open
7,27 USD
High
7,54 USD
Low
7,09 USD
Mkt. cap
125,20 млн
Avg. vol.
580,80 миң
Volume
242,00
52-wk high
22,38 USD
52-wk low
7,09 USD
EPS
-12,92 USD
Beta
1,78
Shares outstanding
17,15 млн
No. of employees
142
Open
7,27 USD
High
7,54 USD
Low
7,09 USD
Mkt. cap
125,20 млн
Avg. vol.
580,80 миң
Volume
242,00
52-wk high
22,38 USD
52-wk low
7,09 USD
EPS
-12,92 USD
Beta
1,78
Shares outstanding
17,15 млн
No. of employees
142
News stories
From web sources and news partners
Profile
Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project. Wikipedia
About Tonix Pharmaceuticals Holding Corp
CEOSeth Lederman
Employees142
Founded2007
HeadquartersБеркли Хайтс, Нью Джерси, Америка Кошмо Штаттары
Sector-
Analyst ratings
Based on 3 analysts giving stock ratings to TNXP in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for TNXP in the last 3 months.
Highest
Current 7,30 USD
65,00 USD (+790,41%)
Average
38,00 USD (+420,55%)
Lowest
22,00 USD (+201,37%)
Analyst
Recommendation
Action
Price target
Projected
Date
James Molloy
Alliance Global Partners
Buy
Reiterated
65,00 USD
+790,4%
09/28/2026
Stacy Ku
TD Cowen
Buy
Maintained
22,00 USD
+201,4%
08/10/2026
Tiago Fauth
Raymond James
Buy
Reiterated
27,00 USD
+269,9%
08/10/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
37,00 USD
+406,8%
03/16/2026
Last report
2026-ж., 10-авг.
Fiscal period
Q2 2026
-2,47 USD / -2,62 USD
+5,58%beat
Revenue / Est. (USD)
13,54 млн / 7,72 млн
+75,38%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
3,29 млн
5,39 млн
6,88 млн
13,54 млн
Cost of goods sold
1,37 млн
1,06 млн
1,58 млн
703,00 миң
Cost of revenue
1,37 млн
1,06 млн
1,58 млн
703,00 миң
Research and development expenses
9,29 млн
16,94 млн
18,21 млн
19,42 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
25,70 млн
35,68 млн
28,62 млн
35,96 млн
Operating expense
34,99 млн
52,62 млн
46,84 млн
55,38 млн
Total operating expenses
36,36 млн
53,68 млн
48,42 млн
56,08 млн
Operating income
-33,07 млн
-48,29 млн
-41,54 млн
-42,54 млн
Other non operating income
-174,00 миң
32,00 миң
-3,00 миң
551,00 миң
EBT including unusual items
-32,01 млн
-46,91 млн
-40,19 млн
-40,55 млн
EBT excluding unusual items
-32,01 млн
-46,91 млн
-40,19 млн
-40,55 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-32,01 млн
-46,91 млн
-40,19 млн
-40,55 млн
Net profit margin
-972,95%
-870,32%
-584,38%
-299,41%
Earnings per share
-3,70
-3,98
-2,93
-2,47
Interest and investment income
1,23 млн
1,34 млн
1,35 млн
1,43 млн
Interest expense
-
-
-
-
Net interest expenses
1,23 млн
1,34 млн
1,35 млн
1,43 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-32,61 млн
-47,80 млн
-40,98 млн
-41,92 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору